<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43595">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958125</url>
  </required_header>
  <id_info>
    <org_study_id>GC-003</org_study_id>
    <nct_id>NCT01958125</nct_id>
  </id_info>
  <brief_title>A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.</brief_title>
  <official_title>A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ElectroCore LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ElectroCore LLC</source>
  <oversight_info>
    <authority>United Kingdom: National Health Service</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will look at a non-invasive treatment for people suffering with chronic and
      episodic headaches.  Study subjects will be randomized to an active treatment or an
      in-active treatment for 2 weeks.  After the 2 weeks all subjects will continue to treat with
      an active treatment for an additional 2 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective double blind, randomized, sham-controlled, multi-center
      investigation designed for comparison of two parallel groups, GammaCore® (active treatment)
      and a sham, (in-active) treatment. The study period begins with a 1-week run-in period,
      followed by a 2 week comparative period when the subjects are randomized (1:1) to either
      active treatment or sham (in-active) treatment. The comparative period will be followed by
      an open label 2 week period, where the subjects in the sham treatment group will switch in
      treatment assignment and receive an active treatment and the active group will continue to
      receive an active treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>severity of headache</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of the pain free rates at 15 minutes following the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of disability</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of scores of disability on a 5 step disability scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Questionnaires answered by the subjects will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of subjects who need to the use of medication for rescue of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain free from symptoms at 30 minutes after treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Cluster Headache</condition>
  <arm_group>
    <arm_group_label>gammacore</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gammacore active device to be used noninvasively to the vagal nerve in the neck.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>inactive gammacore</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>same as the active treatment, but without the therapy treatment provided</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>gammaCore</intervention_name>
    <description>Vagal stimulation</description>
    <arm_group_label>gammacore</arm_group_label>
    <arm_group_label>inactive gammacore</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is 18 years or older

          -  Has been diagnosed with episodic or chronic cluster headache in accordance with the
             ICHD-2 Classification criteria (2ndEd)

          -  Is capable of completing the 5-point pain scale, disability scale and other
             self-assessments

          -  Agrees to refrain from starting new medication aimed to control the cluster headache
             for the duration of the run-in and randomized phase

          -  Is able to provide written Informed Consent

        Exclusion Criteria:1.

          -  Episodic cluster headache sufferers who are not in a cluster headache bout at the
             time of screening and enrollment

          -  2. Need to commence treatment with oral or injectable steroids for eventual
             concomitant medical conditions

          -  3. Has a lesion (including lymphadenopathy), dysaesthesia, previous surgery or
             abnormal anatomy at the GammaCore® treatment site

          -  4. Is currently taking medication for indications other than CH that in the opinion
             of the clinician may interfere with the study

          -  5. Has a history of any cranial aneurysm, intracranial haemorrhage, brain tumours or
             significant head trauma

          -  6. Diagnosed or suspected secondary headache

          -  7. Has other significant pain problem that might confound the study assessments in
             the opinion of the investigator

          -  8. Has known or suspected severe atherosclerotic cardiovascular disease, severe
             carotid artery disease (e.g. bruits or history of transient ischemic attack (TIA) or
             cerebral vascular accident CVA), congestive heart failure (CHF), known severe
             coronary artery disease or recent (5 years) myocardial infarction

          -  9. Has an abnormal baseline ECG (e.g. second and third degree heart block, atrial
             fibrillation, atrial flutter, recent history of ventricular tachycardia or
             ventricular fibrillation, or clinically significant premature ventricular
             contraction)

          -  10. Has had a previous, cervical vagotomy

          -  11. Has uncontrolled high blood pressure

          -  12. Is currently implanted with an electrical and/or neurostimulator device,
             including but not limited to cardiac pacemaker or defibrillator, vagal
             neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or
             cochlear implant

          -  13. Has a history of carotid endarterectomy or vascular neck surgery

          -  14. Has been implanted with metal cervical spine hardware or has a metallic implant
             near the GammaCore stimulation site

          -  15. Has a recent (12 months) or repeated history of syncope

          -  16. Has a recent (12 months) or repeated history of seizure

          -  17. Has a known history or suspicion of substance abuse or addiction, or overuse of
             acute headache medication

          -  18. Has psychiatric or cognitive disorder and/or behavioural problems which in the
             opinion of the clinician may interfere with the study

          -  19. Is pregnant, nursing, thinking of becoming pregnant in the next 6 weeks 20. Is
             participating in any other therapeutic clinical investigation or has participated in
             a clinical trial in the preceding 30 days

          -  21. Is a relative of or an employee of the investigator or the clinical study site
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter J. Goadsbury, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital, Dept for Neurology and Clinical Neurosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annelie Andersson, PM</last_name>
    <phone>+46 (0)72 1803076</phone>
    <email>annelie.andersson@electrocoremedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Glostrup Hospital, Danish Headache Centre</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rigmor Jensen, Prof.</last_name>
      <phone>+45 3863 2062</phone>
      <email>rigmor.jensen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Malene Danoe, SC</last_name>
      <phone>+45 3863 2062</phone>
      <email>malene.kjaergaard.danoe@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Rigmor Jensen, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Lyckhage, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westdeutches Kopfschmerzzentrum</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kasja Rabe, MD</last_name>
      <phone>+49 (0)201 4369624</phone>
      <email>kasja.rabe@uni-due.de</email>
    </contact>
    <contact_backup>
      <last_name>Melina Braunstein, SC</last_name>
      <phone>+49 (0)201 43696-0</phone>
      <email>melina.braunstein@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Kasja Rabe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steffen Nägel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maja Bak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kopfschmerzklinik Königstein</name>
      <address>
        <city>Königstein im Taunus</city>
        <zip>D-61462</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charly Gaul, MD</last_name>
      <phone>+49 (0)6174 29040</phone>
      <email>c.gaul@migraene-klinik.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina Stillger, SC</last_name>
      <phone>+49 (0)6174 29040</phone>
      <email>s.stillger@migraene-klinik.de</email>
    </contact_backup>
    <investigator>
      <last_name>Charly Gaul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center, Neurology Department, K5-Q-104</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel D. Ferrari, Prof.</last_name>
      <phone>+31 71 5262895</phone>
      <email>m.d.ferrari@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ilse de Coo, MD</last_name>
      <phone>+31 71 5261645</phone>
      <email>i.f.de_coo@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Michel D. Ferrari, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilse de Coo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gisela M. Terwindt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leopoldine A. Wilbrink, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary, Neurology Department</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fayyaz Ahmed, MD</last_name>
      <phone>+44 (0)1482 672444</phone>
      <email>fayyaz.ahmed@hey.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Anwar Osman, MD</last_name>
      <phone>+44 (0)7870 167407</phone>
      <email>anwar.osman@hey.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Fayyaz Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anwar Osman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free, Dept for Neurology and Clinical Neurosciences</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Goadsby, Prof.</last_name>
      <phone>+44 0 20 7794 0500</phone>
      <email>profgoadsby.research@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Juana Marin, MD</last_name>
      <phone>+44 (0)20 7794 0500</phone>
      <email>profgoadsby.research@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Goadsby, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juana Marin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Nesbitt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Southern Hospital, Neurology Department</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alok Tyagi, MD</last_name>
      <phone>+44 (0)141 2017542</phone>
      <email>aloktyagi@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Anissa Benchiheub, SC</last_name>
      <phone>+44 (0)141 2329515</phone>
      <email>anissa.benchiheub@ggc.scot.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alok Tyagi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Walton Center, Neurology Department</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Silver, MD</last_name>
      <phone>+44 (0)151 5253611</phone>
      <email>drnicksilver@googlemail.com</email>
    </contact>
    <contact_backup>
      <last_name>Kate O'Hanlon, SC</last_name>
      <phone>+44(0)151 5295666</phone>
      <email>kate.o'hanlon@thewaltoncentre.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Silver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helene Banks, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>October 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vagus nerve stimulation</keyword>
  <keyword>vagal nerve stimulation</keyword>
  <keyword>nVNS</keyword>
  <keyword>VNS</keyword>
  <keyword>cluster headache</keyword>
  <keyword>non invasive</keyword>
  <keyword>gammacore</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cluster Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
